| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/03/2009 | CA2334821C Chemical synthesis of morpholine derivatives |
| 02/03/2009 | CA2315050C Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
| 02/03/2009 | CA2282654C Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder |
| 02/03/2009 | CA2185565C Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases |
| 01/29/2009 | WO2009015000A1 Pyrazole urea derivatives used as kinase inhibitors |
| 01/29/2009 | WO2009014770A2 Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
| 01/29/2009 | WO2009014127A1 Composition for prevention or treatment of disease associated with the production of autoantibody |
| 01/29/2009 | WO2009014105A1 Novel carboxylic acid and antidepressant composition containing the same as active ingredient |
| 01/29/2009 | WO2009014097A1 Novel histidine derivative |
| 01/29/2009 | WO2009013885A1 Inhibitor of the differentiation of t cells into th1 cells |
| 01/29/2009 | WO2009013594A2 Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process |
| 01/29/2009 | WO2009013550A1 Composition and treatment |
| 01/29/2009 | WO2009013535A1 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor |
| 01/29/2009 | WO2009013506A1 Cannabidiol for use in the treatment of transmissible neurodegenerative conditions |
| 01/29/2009 | WO2009013390A1 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases |
| 01/29/2009 | WO2009013335A1 Organic compounds |
| 01/29/2009 | WO2009013299A2 Novel bradykinin b1 antagonists |
| 01/29/2009 | WO2009013293A1 Substituted cyclohexanecarboxamides useful as bace inhibitors |
| 01/29/2009 | WO2009012741A1 Method for the synthesis of a-ring aromatized acetyl minocyclines |
| 01/29/2009 | WO2009012647A1 Preparation methods of quinazoline derivatives and their pharmaceutical uses |
| 01/29/2009 | WO2009012571A1 Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| 01/29/2009 | WO2009012569A1 TREATING OR AMELIORATING A NEUROINFLAMMATORY OR DEMYELINATING DISORDER WITH PROLACTIN AND INTERFERON-β |
| 01/29/2009 | WO2008149177A3 Marine lipid compositions and uses thereof |
| 01/29/2009 | WO2008148801A3 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 01/29/2009 | WO2008138536A3 Antibody directed to g protein coupled receptors (gpcr) |
| 01/29/2009 | WO2008089453A9 Inhibitors of d-amino acid oxidase |
| 01/29/2009 | WO2008085074A8 1, 3-dihydroimidazoles for treating cardiovascular disorders |
| 01/29/2009 | WO2008063781A3 Chemical compounds as cannabinoid receptor ligands |
| 01/29/2009 | WO2008059372A3 Crystal form of (3r,5r)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-metyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoic acid sodium salt |
| 01/29/2009 | WO2008004067A3 Alpha-2-delta-1 selective compounds for disorders of the nervous system |
| 01/29/2009 | WO2007061661A4 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/29/2009 | US20090030188 Activatable recombinant neurotoxins |
| 01/29/2009 | US20090030182 Activatable recombinant neurotoxins |
| 01/29/2009 | US20090030083 Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
| 01/29/2009 | US20090030080 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 01/29/2009 | US20090030041 N-substituted N-(4-piperidinyl) Amide Derivative |
| 01/29/2009 | US20090030040 Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| 01/29/2009 | US20090030038 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor |
| 01/29/2009 | US20090030036 Nuclear receptor binding agents |
| 01/29/2009 | US20090030035 exo-3-(3 ,4-Dichloro-phcnoxy)-8-aza-bicyclo[3.2.1]oct-6-ene; antidepressants, psychological disorders |
| 01/29/2009 | US20090030033 Novel Compounds 894 |
| 01/29/2009 | US20090030029 Novel benzonaphthyridines |
| 01/29/2009 | US20090030026 Sustained release formulations of nalbuphine |
| 01/29/2009 | US20090030025 Trans-fused chromenoisoquinolines synthesis and methods for use |
| 01/29/2009 | US20090030023 Pyrimidine compounds and medicinal composition thereof |
| 01/29/2009 | US20090030019 Purine derivatives having, in particular, anti-proliferative properties, and their biological uses |
| 01/29/2009 | US20090030018 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex |
| 01/29/2009 | US20090030014 Indole Derivative Having Pgd2 Receptor Antagonist Activity |
| 01/29/2009 | US20090030013 Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments |
| 01/29/2009 | US20090030007 crystalline form of trans-1 {4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride (Form III) Cariprazine {RGH-188); Dysfunction of the dopaminergic neurotransmitter system is involved in the pathology of several neuropsychiatric and neurodegenerative disorders |
| 01/29/2009 | US20090030003 Amino-heterocyclic compounds |
| 01/29/2009 | US20090029998 Thiazole Derivatives and Use Thereof |
| 01/29/2009 | US20090029997 Thiazole Derivatives and Use Thereof |
| 01/29/2009 | US20090029991 Benzamide derivatives useful as histone deacetylase inhibitors |
| 01/29/2009 | US20090029986 such as 1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-2-yl-methanone, used as human orexin receptor antagonist, for the treatment of obesity and insomnia |
| 01/29/2009 | US20090029985 Pyridazine compounds and methods |
| 01/29/2009 | US20090029978 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
| 01/29/2009 | US20090029977 Dual modulators of 5ht2a and d3 receptors |
| 01/29/2009 | US20090029969 1-(2,4-dichlorophenyl)-4-methyl-5-(5-(pent-1-enyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; cannabinoid receptor modulator; liver fibrosis, obesity, type II diabetes, atherosclerosis, analgesia, haemorrhagic shock, ischemia, liver cirrhosis, neurodegenerative diseases |
| 01/29/2009 | US20090029967 Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| 01/29/2009 | US20090029965 Vasopressin V1a Antagonists |
| 01/29/2009 | US20090029960 Macrocyclic compounds useful as base inhibitors |
| 01/29/2009 | US20090029959 Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants |
| 01/29/2009 | US20090029947 Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| 01/29/2009 | US20090029943 Glucosamine and Derivatives Thereof Useful as TG Inhibitors |
| 01/29/2009 | US20090029929 Decoy Nucleic Acid to Synoviolin Gene Promoter |
| 01/29/2009 | US20090029415 Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, X-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/29/2009 | US20090029400 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 01/29/2009 | US20090029361 Growth differentiation factor-7 |
| 01/29/2009 | US20090028951 Compositions for Oral Administration of Sustained Release Glutathione, Methods for Their Production and Uses Thereof |
| 01/29/2009 | US20090028908 Methods for treating neurogenic inflammation |
| 01/29/2009 | US20090028904 Novel cochleate formulations |
| 01/29/2009 | US20090028882 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
| 01/29/2009 | US20090028873 Substituted cyclohexanols |
| 01/29/2009 | US20090028869 Diagnosis and treatment of alzheimer's and other neurodementing diseases |
| 01/29/2009 | US20090028851 Novel Antibodies Directed to the Mammalian Eag1 Ion Channel Protein |
| 01/29/2009 | US20090028829 Fusion proteins for the treatment of CNS |
| 01/29/2009 | US20090028825 Compositions and Methods for Studying and Treating Inflammatory Diseases and Disorders |
| 01/29/2009 | US20090028824 Systems and methods for delivering drugs |
| 01/29/2009 | US20090028816 Treatment of depression, psychosis, and anxiety |
| 01/29/2009 | US20090028802 Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same |
| 01/29/2009 | US20090028787 Novel Heteroaryl Substituted Benzothiazoles |
| 01/29/2009 | DE102007033359A1 Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen Use of a granulin or granulin-like compound for the treatment or prophylaxis of chronic pain |
| 01/29/2009 | CA2694251A1 Novel b1-antagonists |
| 01/29/2009 | CA2693996A1 Treating or ameliorating neuroinflammatory or demyelinating disorders with prolactin and an immunomodulator |
| 01/29/2009 | CA2693921A1 Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| 01/29/2009 | CA2693915A1 Pyrazolo[1,5-a]pyrimidine derivatives |
| 01/29/2009 | CA2693804A1 2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases |
| 01/29/2009 | CA2693377A1 5-pyridinone substituted indazoles |
| 01/29/2009 | CA2692824A1 Novel histidine derivatives |
| 01/28/2009 | EP2019098A1 Suppressor of expression of mcp-1, and ameliorating agent for inflammatory disease, pharmaceutical, supplement, food, beverage or food additive using the suppressor |
| 01/28/2009 | EP2019094A1 Heterocyclic type cinnamide derivative |
| 01/28/2009 | EP2019093A1 Urea type cinnamide derivative |
| 01/28/2009 | EP2018874A2 Pharmaceutical compositions for the prevention and treatment of central nervous system disorders comprising a nicotinic compound and an acetylcholinesterase inhibitor |
| 01/28/2009 | EP2018872A1 Pharmaceutical product |
| 01/28/2009 | EP2018862A1 Substituted piperidines as therapeutic compounds |
| 01/28/2009 | EP2018855A1 Pharmaceutical agent |
| 01/28/2009 | EP2018854A1 Novel combinations of neramexane for the treatment of neurodegenerative disorders |
| 01/28/2009 | EP2018852A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 01/28/2009 | EP2018380A2 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |